Workflow
Brainstorm Cell Therapeutics(BCLI)
icon
Search documents
Brainstorm Cell Therapeutics(BCLI) - 2020 Q2 - Quarterly Report
2020-08-05 11:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware ...
Brainstorm Cell Therapeutics(BCLI) - 2020 Q1 - Earnings Call Transcript
2020-05-10 19:46
BrainStorm Cell Therapeutics Inc. BCLI) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Sean Leous - ICR Westwicke Chaim Lebovits - President and Chief Executive Officer Preetam Shah - EVP and Chief Financial Officer Ralph Kern - President and Chief Medical Officer David Setboun - Chief Operating Officer Conference Call Participants Marcia Kaplan - Ameriprise Financial John Evans - Raymond James Operator Greetings and welcome to the BrainStorm Cell Therapeutics First Quarter 202 ...
Brainstorm Cell Therapeutics(BCLI) - 2020 Q1 - Quarterly Report
2020-05-07 10:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q4 - Earnings Call Transcript
2020-02-18 18:01
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2019 Results Earnings Conference Call February 18, 2020 8:00 AM ET Company Participants Sean Leous - ICR Westwicke Chaim Lebovits - President and Chief Executive Officer Preetam Shah - EVP and Chief Financial Officer Ralph Kern - Chief Operating and Chief Medical Officer Arturo Araya - Chief Commercial Officer Conference Call Participants Jason Kolbert - Dawson James Operator Greetings and welcome to the BrainStorm Cell Therapeutics Fourth Quarter 2019 Earn ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q4 - Annual Report
2020-02-18 12:01
UNITED STATES Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market LLC (Nasdaq Capital Market) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO _________ ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q3 - Earnings Call Transcript
2019-11-14 18:51
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) Q3 2019 Earnings Conference Call November 14, 2019 8:00 AM ET Company Participants Sean Leous – ICR Westwicke Chaim Lebovits – President and Chief Executive Officer Preetam Shah – Chief Financial Officer Ralph Kern – Chief Operating Officer, Chief Medical Officer Arturo Araya – Chief Commercial Officer Conference Call Participants David Bautz – Zacks Small Cap Research Jason Kolbert – Dawson James Jack Mayer – Private Investor Jason McCarthy – Maxim Operator ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q3 - Quarterly Report
2019-11-14 11:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Dela ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q2 - Earnings Call Transcript
2019-08-13 17:31
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2019 Results Earnings Conference Call August 13, 2019 8:00 AM ET Company Participants Sean Leous - ICR Westwicke Chaim Lebovits - President and Chief Executive Officer Eyal Rubin - Executive Vice President and Chief Financial Officer Ralph Kern - Chief Operating Officer and Chief Medical Officer Conference Call Participants David Bautz - Zacks Small Cap Research Jason Kolbert - Dawson James John Rice - Wells Fargo Operator Good day and welcome to BrainStorm ...
Brainstorm Cell Therapeutics(BCLI) - 2019 Q2 - Quarterly Report
2019-08-13 10:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market LLC (Nasdaq Capital Market) FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...